Form D · Pharmaceuticals
NeuroVive Pharmaceutical AB
81 Lund, V7 · CIK 0001643349
Offering snapshot reported May 27, 2015 · SEC filing
- Reported sold
- $7.46M Offering amount: $25M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 8, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 27, 2015 | Initial | $7,462,732 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $597K
- Finders' fees
- $0
- Form D file number
- 021-240553
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Chardan Capital Markets, LLC | 120128 |
Source: Form D, filed May 27, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory Batcheller | Director, Executive |
| Anna Malm Bernsten | Director |
| Mikael Bronnegard | Executive |
| Eskil Elmer | Executive |
| Arne Ferstad | Director |
| Boel Flodgren | Director |
| Catharina Johansson | Executive |
| Marcus Keep | Director |
| Helena Levander | Director |
| Jan Nilsson | Executive |
| Carl Fredrick Olsson | Director |
| Helmuth Von Moltke | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Medicon Village Se 223
81 Lund, V7, None
81 Lund, V7, None